NYSE:ABBVBiotechs
A Fresh Look at AbbVie’s (ABBV) Valuation After Q3 Results, Margin Decline, and Dividend Boost
AbbVie delivered third-quarter results that beat analyst expectations for both revenue and earnings per share, driven by continued strength in its immunology and neuroscience portfolios. However, headlines also focused on the company’s operating margin drop and reduced full-year earnings guidance.
See our latest analysis for AbbVie.
This flurry of news comes as AbbVie’s share price has climbed 22% year-to-date, while its 1-year total shareholder return stands at nearly 14%. Strong product...